Provectus CEO converts preferred to 113,280 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Provectus Biopharmaceuticals, Inc. CEO, director and 10% owner Edward Pershing reported a conversion on November 13, 2026: the 8% unsecured convertible promissory note automatically converted into 11,328 Series D-1 preferred shares at $2.862 per share, and those preferred shares converted into 113,280 common shares at 10 common shares per preferred share. His reported direct common-stock holdings after the transaction were 3,055,221 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | 8% Unsecured Convertible Promissory Note F3, F4 | -- | $0.00 | -- |
| Exercise | Series D-1 Convertible Preferred Stock F1, F2 | 11,328 | $0.00 | $0.00 |
Footnotes (4)
- F1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- F2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
- F3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
- F4. On November 13, 2026, the 2025 Note converted into 11,328 shares of Series D-1 Preferred Stock.
Key Figures
Key Terms
8% Unsecured Convertible Promissory Note financial
Series D-1 Convertible Preferred Stock financial
Certificate of Designation technical
automatically convert technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
At what price did PVCT’s 2025 Note convert?
When is PVCT Series D-1 preferred stock set to convert automatically?
AI-generated analysis. How Rhea-AI works. Not financial advice.